HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

Taiwan Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


Taiwan Hepatic Encephalopathy Treatment Market Insights

  • According to Reed Intelligence analysis, the Taiwan Hepatic Encephalopathy Treatment Market size was USD 24.14 Million in 2025 and is projected to reach USD 50.63 Million by 2034.
  • The Taiwan market is projected to grow at a CAGR of 8.46% between 2026 and 2034.
  • By segment, Rifaximin emerged as the largest Drug Class in terms of market size in 2025.
  • Lactulose is anticipated to remain the most attractive Drug Class segment, recording the fastest growth during the forecast period.

Other Key Findings


  • In 2025, Taiwan represented 0.97% of the overall global Hepatic Encephalopathy Treatment Market size.
  • United States is projected to lead the global Hepatic Encephalopathy Treatment Market size by 2034.
  • Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
  • Japan is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 102.85 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 24.14 Million
Market Size In 2034 USD 50.63 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 8.46% (2026-2034)
Segmnetation Covered
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports